Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CELZ 
Creative Medical Technology Holdings Inc (CELZ)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/20/2025: CELZ (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $20
1 Year Target Price $20
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -63.19% | Avg. Invested days 19 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/20/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 6.84M USD | Price to earnings Ratio - | 1Y Target Price 20 |
Price to earnings Ratio - | 1Y Target Price 20 | ||
Volume (30-day avg) 1 | Beta 4.91 | 52 Weeks Range 1.69 - 6.90 | Updated Date 06/30/2025 |
52 Weeks Range 1.69 - 6.90 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.81 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -55349.27% |
Management Effectiveness
Return on Assets (TTM) -43.7% | Return on Equity (TTM) -70.45% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -864458 | Price to Sales(TTM) 488.46 |
Enterprise Value -864458 | Price to Sales(TTM) 488.46 | ||
Enterprise Value to Revenue 56.07 | Enterprise Value to EBITDA -1.45 | Shares Outstanding 2580530 | Shares Floating 2167260 |
Shares Outstanding 2580530 | Shares Floating 2167260 | ||
Percent Insiders 1.36 | Percent Institutions 7.8 |
Analyst Ratings
Rating 1 | Target Price 20 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Creative Medical Technology Holdings Inc
Company Overview
History and Background
Creative Medical Technology Holdings, Inc. focuses on biotechnology and stem cell-based therapies. While exact founding year and detailed milestones are difficult to precisely determine due to limited public information, the company has evolved to focus on regenerative medicine.
Core Business Areas
- Immune Modulation: Develops therapies to modulate the immune system using stem cells and related technologies.
- Regenerative Medicine: Focuses on developing treatments for various medical conditions by harnessing the body's own regenerative capabilities.
- Cancer Therapy: Explores cell-based therapies for cancer treatment.
Leadership and Structure
Information on the specific leadership team and organizational structure is not readily available publicly.
Top Products and Market Share
Key Offerings
- ImmCelz: A cell-based immunotherapy platform designed to enhance the immune response to tumors. Market share data is not publicly available. Competitors include companies developing CAR-T cell therapies and other immunotherapies, such as Gilead (GILD) and Novartis (NVS).
- StemSpine: A potential treatment for degenerative disc disease. Market share data is unavailable. Competitors include companies offering surgical and non-surgical treatments for back pain.
Market Dynamics
Industry Overview
The regenerative medicine industry is rapidly growing, driven by increasing demand for innovative therapies for chronic diseases and aging-related conditions. The biotechnology industry is highly competitive and heavily regulated.
Positioning
Creative Medical Technology Holdings Inc. is positioned as a player in the regenerative medicine and immunotherapy space. Its competitive advantage lies in its proprietary technologies and focus on cell-based therapies.
Total Addressable Market (TAM)
The regenerative medicine TAM is projected to reach billions of dollars in the coming years. Creative Medical Technology Holdings Inc. is positioned to capture a portion of this market, although specific TAM share data is not readily available.
Upturn SWOT Analysis
Strengths
- Proprietary technology platforms
- Focus on innovative cell-based therapies
- Potential for disruptive treatments
Weaknesses
- Limited financial resources
- Early-stage development of products
- Dependence on regulatory approvals
- Lack of publicly available information
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Favorable regulatory changes
- Growing demand for regenerative medicine
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Intellectual property disputes
- Limited access to funding
Competitors and Market Share
Key Competitors
- GILD
- NVS
- JNJ
Competitive Landscape
Creative Medical Technology Holdings Inc. faces significant competition from larger, more established pharmaceutical companies with greater resources. Its advantage lies in its innovative technologies, but it must overcome regulatory hurdles and secure funding to compete effectively.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends are difficult to determine without detailed financial data.
Future Projections: Future growth projections are speculative and dependent on successful clinical trials, regulatory approvals, and market adoption.
Recent Initiatives: Recent initiatives involve the continued development of their core product offerings (ImmCelz, StemSpine).
Summary
Creative Medical Technology Holdings Inc. is an early-stage biotechnology company focused on regenerative medicine and immunotherapy. Its proprietary technologies hold promise but face significant challenges related to funding, regulatory approvals, and competition. The company's success depends on successfully navigating these challenges and demonstrating clinical efficacy. Further detail of the company performance is limited due to lack of publicly available information.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website, SEC filings (limited availability), Industry reports.
Disclaimers:
This analysis is based on limited publicly available information and should not be considered financial advice. The biotechnology industry is inherently risky, and investment decisions should be made with caution.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Creative Medical Technology Holdings Inc
Exchange NASDAQ | Headquaters Phoenix, AZ, United States | ||
IPO Launch date 2015-11-06 | Co-Founder, Chairman, President & CEO Mr. Timothy Warbington | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | |
Full time employees 4 | |||
Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT), a allogenic human perinatal tissue derived cell program, ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, which is phase 2, for the treatment of type 1 diabetes; AlloStemSpine (CELZ 201 ADAPT), which is phase 2, for the treatment of chronic lower back pain; Alova, which is in IND-enabling phase, to treat infertility as a result of premature ovarian failure; iPSCelz, which is in pre-clinical stage, a platform to make cell type in the body; StemSpine, a regenerative stem cell procedure to treat degenerative disc disease; OvaStem, a stem cell therapy for premature ovarian failure; CaverStem for erectile dysfunction treatment; and FemCelz for female sexual function treatment. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.